Treatment with rhGH has beneficial effects on growth, body composition and development. The ideal age for starting GH is not clear, although there has been a trend towards starting at younger ages and the dose titration and monitoring of treatment remain controversial.
Unexpected death in infants and children with PWS have been reported in patients with or without rhGH treatment (complicated course of a relatively mild respiratory tract infection, sleep apnea, adenoid/tonsil hypertrophy, hypoventilation orrelated to obesity).
There is suggestion of a high risk period during the first months of GH treatment, with the advice to start at a low dose of rhGH and increasing during the first weeks and months to reach a standard replacement dose (1.0 mg/m 2 /d or 0.035 mg/kg/d).
Background Aim
To study retrospectively children who presented in our multidisciplinary PWS clinic and assess their response to rhGH treatment in terms of auxology, IGF1 concentration and potential complications. 
Patients Results
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Mean change in Ht of 1.37 SDS. 
Pre Treatment Year 1
Mean
Auxology
60% of patients had IGF1 > than +2.0 SDS at 1Yr and the dose of rhGH remained unchanged.
 No patient had worsening of the respiratory status  2/6 patients with previous sleep apnoea discontinued ventilatory support after starting Tx
Conclusions
In patients with PWS early treatment with rhGH results in improved height in the 1 st year with no adverse effect on respiratory function. Only one patient had a brief pause in treatment during spinal surgery. We recommend dose titration using auxology and IGF1 concentration
No correlation between genotype and response to treatment.
